Terrance Mcguire Sells 74,764 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 74,764 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $0.47, for a total transaction of $35,139.08. Following the sale, the director now directly owns 3,840,146 shares in the company, valued at $1,804,868.62. This trade represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.44 on Friday. The stock’s 50-day simple moving average is $0.78 and its two-hundred day simple moving average is $1.02. The stock has a market capitalization of $53.10 million, a price-to-earnings ratio of -0.23 and a beta of 0.53. Invivyd, Inc. has a 52-week low of $0.40 and a 52-week high of $5.20.

Hedge Funds Weigh In On Invivyd

A number of institutional investors and hedge funds have recently made changes to their positions in IVVD. Proficio Capital Partners LLC purchased a new stake in Invivyd during the third quarter valued at approximately $27,000. XTX Topco Ltd grew its position in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after acquiring an additional 15,376 shares during the period. SG Americas Securities LLC increased its stake in shares of Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after purchasing an additional 25,201 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in Invivyd in the 2nd quarter worth $86,000. Finally, Rhumbline Advisers lifted its position in Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after purchasing an additional 82,164 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright lowered their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Invivyd in a report on Thursday, November 21st. Finally, Morgan Stanley decreased their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.